All In Biotech

Drug Trial Radar · NCT03896009

Maximizing Outcomes in Treating Acute Migraine

MOMENTUM: A Randomized, Double-blind, Single-dose, Placebo-controlled Study to Assess the Efficacy and Safety of AXS-07 (Meloxicam and Rizatriptan) for the Acute Treatment of Migraine in Adults

Last checked: Nov 19, 2026Latest source record: Aug 24, 2023 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 1,594 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

1,594

Actual

Start

Mar 4, 2019

Primary completion

Dec 10, 2019

Study completion Dec 10, 2019

Sponsor

Lead sponsor
Axsome Therapeutics, Inc.Industry
Sponsor type
Industry
First posted
Mar 29, 2019

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 65 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

AXS-07 is an oral, investigational medicine consisting of MoSEIC meloxicam and rizatriptan, which is being developed for the acute treatment of migraine with or without aura in adults. AXS-07 tablets are formulated to provide an enhanced rate of absorption of meloxicam. This study is designed to evaluate the efficacy and safety of AXS-07 compared to meloxicam, rizatriptan, and placebo for the treatment of a migraine attack. This is a randomized, double-blind, 4-arm, parallel group, single-dose, placebo-controlled trial. Subjects who successfully complete screening and continue to meet all entry criteria will be randomly assigned to take one dose of either AXS-07, meloxicam, rizatriptan, or placebo upon the occurrence of a qualifying migraine.

Conditions

  • Migraine

Interventions

  • AXS-07 (MoSEIC meloxicam and rizatriptan)Drug

    AXS-07 taken once upon onset of a qualifying migraine.

  • MeloxicamDrug

    Meloxicam taken once upon onset of a qualifying migraine.

  • RizatriptanDrug

    Rizatriptan taken once upon onset of a qualifying migraine.

  • PlaceboDrug

    Placebo taken once upon onset of a qualifying migraine.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percentage of Subjects Reporting Headache Pain FreedomTime frame: Hour 2 following dose administration
  2. Percentage of Subjects With Absence of Most Bothersome SymptomTime frame: Hour 2 following dose administration

Locations

85 sites in 1 country. Site status is shown where the registry gives one.

  • Clinical Research Site

    Birmingham, Alabama

  • Clinical Research Site

    Birmingham, Alabama

  • Clinical Research Site

    Mobile, Alabama

  • Clinical Research Site

    Phoenix, Arizona

  • Clinical Research Site

    Tempe, Arizona

  • Clinical Research Site

    Little Rock, Arkansas

  • Clinical Research Site

    Canoga Park, California

  • Clinical Research Site

    Colton, California

  • Clinical Research Site

    Culver City, California

  • Clinical Research Site

    Encino, California

  • Clinical Research Site

    Los Alamitos, California

  • Clinical Research Site

    Los Angeles, California

  • Clinical Research Site

    Oceanside, California

  • Clinical Research Site

    Pomona, California

  • Clinical Research Site

    Redlands, California

  • Clinical Research Site

    Riverside, California

  • Clinical Research Site

    San Diego, California

  • Clinical Research Site

    Santa Monica, California

  • Clinical Research Site

    Spring Valley, California

  • Clinical Research Site

    Walnut Creek, California

  • Clinical Research Site

    Waterbury, Connecticut

  • Clinical Research Site

    Clermont, Florida

  • Clinical Research Site

    DeLand, Florida

  • Clinical Research Site

    Fernandina Beach, Florida

  • Clinical Research Site

    Hallandale, Florida

  • Clinical Research Site

    Hialeah, Florida

  • Clinical Research Site

    Hollywood, Florida

  • Clinical Research Site

    Jacksonville, Florida

  • Clinical Research Site

    Lake City, Florida

  • Clinical Research Site

    Lake Worth, Florida

  • Clinical Research Site

    Miami, Florida

  • Clinical Research Site

    Ocoee, Florida

  • Clinical Research Site

    Orange City, Florida

  • Clinical Research Site

    Orlando, Florida

  • Clinical Research Site

    Ormond Beach, Florida

  • Clinical Research Site

    South Miami, Florida

  • Clinical Research Site

    Sunrise, Florida

  • Clinical Research Site

    Tampa, Florida

  • Clinical Research Site

    Atlanta, Georgia

  • Clinical Research Site

    Atlanta, Georgia

Showing 40 of 85 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.